Literature DB >> 1969448

Langerhans cells that migrate to skin after intravenous infusion regulate the induction of contact hypersensitivity.

P D Cruz1, R E Tigelaar, P R Bergstresser.   

Abstract

Intravenous infusion of hapten-derivatized epidermal cells (EC) in syngeneic mice leads to two competing signals for contact hypersensitivity (CH), a dominant effector signal attributable to Langerhans cells (LC) and a suppressor signal from Thy-1+ EC. In vitro exposure of LC to low dose ultraviolet B (UVB) radiation before hapten-derivatization and infusion not only results in the abrogation of their effector signal but also causes the down-regulation of subsequent CH responses. To delineate the relevance of i.v. immunization to the study of CH and of LC as the immunologic targets of low dose UVB radiation, we examined the migratory and immunogenic properties of EC after i.v. infusion. Unsorted EC migrated from blood to skin and lymphoid tissues, reaching steady state distributions at 16 h after infusion. No significant differences were observed between the trafficking of EC in syngeneic and allogeneic transfers. LC localized preferentially to skin, whereas Thy-1+ EC trafficked to skin, the thymus, mesenteric lymph nodes, and spleen. The pattern of trafficking of unirradiated and low dose UVB-irradiated LC were identical, suggesting that low dose UVB radiation had little effect on LC migration. Finally, skin graft experiments demonstrated i.v. infused, hapten-derivatized LC that migrate to skin to retain their capacity to induce CH, a property that was converted by in vitro pretreatment with low dose UVB radiation into down-regulation. These findings confirm the relevance and utility of the i.v. immunization model in the study of CH and the influence of low dose UVB on this immune response. Our data also provide a basis for investigating the role of disparate trafficking patterns in generating effector and suppressor signals when hapten-derivatized EC are employed for CH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969448

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Langerhans cells serve as immunoregulatory cells by activating NKT cells.

Authors:  Atsushi Fukunaga; Noor M Khaskhely; Ying Ma; Coimbatore S Sreevidya; Kumiko Taguchi; Chikako Nishigori; Stephen E Ullrich
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

2.  Regulation of contact hypersensitivity by interleukin 10.

Authors:  T A Ferguson; P Dube; T S Griffith
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

3.  Epidermal Langerhans cells are not required for UV-induced immunosuppression.

Authors:  Liangchun Wang; Stephen C Jameson; Kristin A Hogquist
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

4.  Sensitizing capacity of Langerhans' cells obtained from ultraviolet-B-exposed murine skin.

Authors:  R Dai; J W Streilein
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

5.  A critical role for the proapoptotic protein bid in ultraviolet-induced immune suppression and cutaneous apoptosis.

Authors:  Sanjay Pradhan; Hee Kyung Kim; Christopher J Thrash; Maureen A Cox; Sudheer K Mantena; Jian-He Wu; Mohammad Athar; Santosh K Katiyar; Craig A Elmets; Laura Timares
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 6.  The balance between immunity and tolerance: the role of Langerhans cells.

Authors:  K Mutyambizi; C L Berger; R L Edelson
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 7.  Photoimmunology--illuminating the immune system through photobiology.

Authors:  Justin Leitenberger; Heidi T Jacobe; Ponciano D Cruz
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759

8.  A skin homing molecule defines the langerhans cell progenitor in human peripheral blood.

Authors:  D Strunk; C Egger; G Leitner; D Hanau; G Stingl
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.